GeoVax Labs Raises $6 Million Through Public Offering

GeoVax Labs has announced a $6 million public offering, raising gross proceeds of approximately $6 million. The company plans to use the funds for working capital and general corporate purposes. GeoVax is a clinical-stage biotechnology company focused on developing vaccines against infectious diseases and therapies for solid tumor cancers. The offering includes shares of common stock and warrants to purchase additional shares, with the proceeds intended for working capital and general corporate purposes.